Clinical trial NCT05935527: Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon
Official title: Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Lower Eyelid Steatoblepharon
Keywords: Steatoblepharon
Eyebag
Under eyelid
Lead sponsor: Peregrine Ophthalmic
Sponsor class: INDUSTRY
First posted: 2023-07-07
Enrollment: 50
Sex: ALL
Minimum age (years): 22
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: This trial is testing a drug to see if multiple injections to the undereye bags of selected patients decreases the volume of the eyebags as compared to placebo. Subjects will be randomized to receive either one of two doses of POLAT-001 or placebo. POLAT-001 will be injected into the eyebags at three of the visits. Each subject will attend 7-10 clinic visits over 98 to 140 days total to assess efficacy and safety.

Detailed description: This trial is a proof-of-concept trial and is testing a drug to see if multiple injections to the undereye bags of selected patients decreases the volume of the eyebags as compared to placebo. Subjects will be randomized to receive either one of two doses of POLAT-001 (1 mg/mL or 2 mg/mL) or placebo (normal saline). POLAT-001 will be injected into the eyebags at three of the visits. Each subject will attend 7-10 clinic visits total over 98 to 140 days to assess efficacy and safety. Subjects assigned to placebo will crossover to receive active treatment. Efficacy will be determined using questionnaires and photography. Safety will be assessed by subject-reported events and investigator observations of the subjects.

Eligibility criteria: Inclusion Criteria:

* Adult subjects, 22 years or older with moderate to severe convexity or fullness associated with periorbital fat.
* Subject has moderate to severe eyebags per Goldberg and Simon's Orbital Fat Grading System, per protocol requirements.
* Willing and able to attend all study visits.

Exclusion Criteria:

* Any signs or symptoms of periorbital disease in the study eye and related complications, as determined by the investigator.
* Active thyroid eye disease, chronic ocular inflammatory orbital disease or other ophthalmic disease that could confound study results.
* Evidence of infection, or clinically significant periocular, periorbital or conjunctival inflammation or conditions that in the opinion of the investigator would constitute a risk or could confound the study results.
* History of hypersensitivity to prostaglandin analogs or prostaglandin PF2alpha treatments.
* Known hypersensitivity to any component of the investigational product formulation.
* Use of periocular corticosteroids within 2 months prior to Screening.
* Use of intravitreal (IVT) injections within 3 weeks prior to Screening in the study eye.
* Surgical or laser treatment of the eye or surrounding anatomical structures within 6 months prior to Screening in the study eye.
* Previous history of lower incisional eyelid surgery.
* Previous history of undereye lid tattoo or underage lash extensions.
* Previous history of infra-orbital or anterior medical cheek fillers within 24 months prior to Screening.
* The subject has received botulinum toxin treatment of the inferior pretarsal orbicularis oculi muscle within 6 months of the first injection.
* History of ocular trauma in the study eye within 6 months prior to Screening.
* Any concurrent disease that would require medical or surgical intervention during the study in the study eye (e.g., retinal detachment, significant cataract, uncontrolled glaucoma).
* Facial nerve injury or abnormal weakness, other facial rejuvenation injections (not including botulinum toxin) in the treated area, facial surgery, or facial trauma within 3 months prior to Screening. History or concurrent systemic condition that would preclude the safe administration of the study treatment or confound the results of the safety (e.g., renal or hepatic impairment).
* Any laboratory findings that based on clinical assessment of the investigator would place the subject at risk or could confound th study results.
* Significant infraorbital vascular prominence.
* Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control.
* Participation in an interventional clinical study within 30 days prior to Screening.
* Any other criterion that based on the clinical judgement of the investigator may place the subject at risk or confound study results.

Primary outcomes:
measure: Mean change of photonumeric volume of eyebags in the POLAT-001 treated and placebo dose groups as measured by a 3D photography system
timeFrame: Baseline to 28 days after the last treatment cycle
Secondary outcomes:
measure: Proportion of eyebags in the POLAT-001 treated and placebo dose groups with at least 10% reduction in photonumeric volume as measured by a 3D photography system
timeFrame: Baseline to 28 days after the last treatment
measure: Proportion of eyebags in the POLAT-001 treated and placebo dose groups with at least 30% reduction in photonumeric volume as measured by a 3D photography system
timeFrame: Baseline to 28 days after the last treatment cycle
measure: Mean change in photonumeric volume of eyebags between the POLAT-001 treated high and low dose groups as measured by a 3D photography system
timeFrame: Baseline to 28 days after the last treatment cycle
Other outcomes:
Locations:
city: Newport Beach
country: United States
facility: Medical Associates, Inc.
state: California
city: Coral Gables
country: United States
facility: Skin Associates of South Florida
state: Florida
city: Pflugerville
country: United States
facility: Austin Institute for Clinical Research
state: Texas
Study officials:
References: